<DOC>
	<DOCNO>NCT00059644</DOCNO>
	<brief_summary>Ecraprost lipid emulsion develop treatment Critical leg ischemia ( CLI ) , severe form peripheral arterial disease ( PAD ) . This trial design assess efficacy safety drug treatment CLI .</brief_summary>
	<brief_title>Efficacy/Safety Ecraprost Lipid Emulsion Treatment Critical Leg Ischemia Due Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Critical leg ischemia ( CLI ) define distal extremity pain rest , peripheral ischemic ulcer ( ) , severe hemodynamic impairment diagnose ankle systolic pressure , toe systolic pressure TcPO2 The subject exhaust standard revascularization treatment option time . Subjects previous major amputation ( ankle ) Subjects end stage renal disease ( ESRD ) define significant renal dysfunction evidence estimate creatinine clearance &lt; 20 cc/min , receive chronic hemodialysis therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Ecraprost lipid emulsion</keyword>
	<keyword>CLI</keyword>
	<keyword>peripheral</keyword>
	<keyword>vascular</keyword>
	<keyword>amputation</keyword>
	<keyword>Critical Limb Ischemia due peripheral arterial disease</keyword>
</DOC>